Parker Waichman LLP

Genzyme Signs Consent Decree, Shortage of Thyroid Cancer Medicine Expected

Massachusetts’ drug manufacturing plant, relinquishing $175 million to the federal government, said the U.S. Food and Drug Administration (FDA). The consent degree agrees to correct manufacturing quality violations at its Allston manufacturing facility; the $175 million represents unlawful profits from the sale of products made at the plant. Under the consent decree of permanent injunction, […]

Massachusetts’ drug manufacturing plant, relinquishing $175 million to the federal government, said the U.S. Food and Drug Administration (FDA).

The consent degree agrees to correct <"https://www.yourlawyer.com/practice_areas/defective_drugs">manufacturing quality violations at its Allston manufacturing facility; the $175 million represents unlawful profits from the sale of products made at the plant. Under the consent decree of permanent injunction, Allston also agreed to adhere to a strict timetable to bring the plant in line with the FDA’s regulatory requirements. The payment—known as a disgorgement—involves the company giving up profits obtained by improper or illegal acts.

The decree was agreed to by Genzyme; Genzyme Chief Executive Officer, Henri A. Termeer; Genzyme Senior Vice President for Manufacturing Sciences and Technical Operations, W. Blair Okita; Genzyme Senior Vice President for Global Product Quality, Ronald Branning. The decree was filed in the U.S. District Court for the District of Massachusetts on May 24, 2010 and is subject to court approval.

Genzyme is a sole supplier of several enzyme replacement drugs for injection that are used to treat rare genetic disorders. During an inspection of the Allston plant from October 8, 2009, until November 13, 2009, FDA inspectors found Genzyme’s systems for ensuring manufacturing quality were inadequate, resulting in production delays; critical shortages of medically necessary products to consumers; and drugs contaminated with metal, fiber, rubber, and glass particles. These problems violated the FDA’s regulations for manufacturing practice. Genzyme also temporarily suspended manufacturing of some products due to a viral contamination in a bioreactor that makes bulk amounts of its drugs. This resulted in additional drug shortages.

“It is critical for the safety of the drug supply that companies comply with basic manufacturing standards. FDA takes these obligations very seriously and expects manufacturers to do the same,” said Joshua Sharfstein, M.D., FDA principal deputy commissioner.

Cerezyme, Fabrazyme, Myozyme, and Thyrogen are drug products that undergo all or some stage of manufacture at the Allston plant. Cerezyme treats Gaucher’s disease, which causes fatty substances to accumulate in the liver, spleen, and other organs. Fabrazyme treats Fabry disease, which prevents the body from breaking down oils and fats that build up in the eyes and kidneys. Myozyme treats Pompe disease, a muscular disorder. Thyrogen is used to diagnose thyroid cancer.

BizJournals pointed out that the enforcement and remediation actions will lead to a drug shortage for Genzyme of Thyrogen and that the FDA has written to health care providers about the issue. The FDA wrote that it will limit Thyrogen to specific patients most in need of the medication until Genzyme either corrects its manufacturing problems or transfers specific procedures said BizJournals. The FDA developed criteria to identify critical need patients—those with a high risk of cancer recurrence or for side effects associated with withdrawing treatment—said BizJournals. The problem should not impact children, said BizJournals, because the FDA determined that Thyrogen is not considered medically necessary for this group since children are, “more likely to tolerate a short period of hypothyroidism.”

Genzyme also just released a supply update on Cerezyme, saying it expects to ship at 50 percent of demand through the June/July and expects shipments of Fabrazyme to continue at 30 percent of demand through the third quarter of 2010, said BizJournals.

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
Positive: Professionalism , Quality , Responsiveness , Value
Emma PyfromWard
2 years ago
5 Star Reviews 150
I had awesome experience with them. Nice and straight forward process. I want to thank Parker & Waichman for and excellent job.
Vic
6 years ago
5 Star Reviews 150
Parker Waichman handled my case very well and obtained a fantastic result. The team representing me had me informed of the progress from begining to end. My attorney Joonho fought very hard for me and his paralegal Meredith Ippolito was exceptional fielding my many questions and making sure everything was getting done as it was supposed too. I cant thank my PW team enough for handling my case professionally and for the outstanding result!
Paul Ulitsky
a year ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038